LIFECORE BIOMEDICAL INC DE
For the period ended Aug 25, 2024. Filed Oct 4, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Aug 25, 2024 · Filed Oct 4, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Inventories
- Inventories
Inventories primarily consist of in-process and finished goods related to sterile injectable pharmaceutical products in syringes, vials and cartridges. This includes premium, pharmaceutical grade HA in bulk form as well as formulated and filled syringes, vials and cartridges for injectable products used in treating a broad spectrum of medical conditions and procedures.
Inventories are stated at the lower of cost (using the first-in, first-out method) or net realizable value. Inventories consisted of the following:
| August 25, 2024 | May 26, 2024 | |
|---|---|---|
| Finished goods | $15,287 | $14,924 |
| Raw materials | 15,515 | 14,555 |
| Work in process | 12,072 | 11,915 |
| Gross inventories | 42,874 | 41,394 |
| Less: Inventory reserve | (1,232) | (1,415) |
| Inventories, net | $41,642 | $39,979 |
Adjustments to inventory are determined at the raw materials, work-in-process, and finished good levels to reflect obsolescence or impaired balances. Factors influencing inventory obsolescence include changes in demand, product life cycle, product pricing, physical deterioration, and quality concerns. The Company recorded adjustments of $1,217 and $776 to record inventory to its net realizable value as of August 25, 2024 and May 26, 2024, respectively.
The Company’s inventory serves as part of the collateral for certain of the Company’s debt arrangements. Refer to Note 10 – Debt for additional discussion on the Company’s debt arrangements and related collateral.
-11-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.